NBC News Social Media Editor Evan Rosenfeld Tweeted Earlier: Elon Musk says he projects Twitter to be cash flow break even next year, as opposed to -$3B this year
https://twitter.com/Evan_Rosenfeld/status/1605447805505503233
Par Pacific Announces Management Promotions; Says William Monteleone Appointed President Effective Jan. 1 2023, Says Shawn Flores Promoted To Senior Vice President, Chief Financial Officer
Par Pacific Holdings, Inc. (NYSE:PARR) ("Par Pacific" or the "Company") today announced the appointment of William Monteleone as President effective January 1, 2023. In his new role,
General Dynamics Appoints Aiken As Executive Vice President And CFO; Marzilli To Retire
General Dynamics (NYSE:GD) announced today that it has appointed chief financial officer Jason Aiken as executive vice president of the Technologies segment effective January 1, 2023.
Oragenics, Inc. Announces New Chairman Of The Board Of Directors Succeeding Dr. Frederick W. Telling
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of
Banc Of California Announces Executive Promotions; John Sotoodeh, Has Been Promoted To COO Of The Company And The Bank; Hamid Hussain Appointed To President Of The Bank
Banc of California, Inc. (NYSE:BANC) (the "Company"), the holding company for Banc of California, N.A. (the "Bank"), today announced the promotions of several senior executives effective January 1,
Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing
Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to CEO Adi Zuloff-Shani.